Funded Biotechnology Startups in China
The 13 entries span June 2020 through November 2025, with four rounds closing in November 2025 alone — JGene Biotechnology (Shenzhen, Series A), U-Sweet Bi…
The 13 entries span June 2020 through November 2025, with four rounds closing in November 2025 alone — JGene Biotechnology (Shenzhen, Series A), U-Sweet Biotechnology (Changzhou, Series A), Zhonghe Gene (Dongli, Seed), and Taihao Biotechnology (Beijing, Series A). Shenzhen and Shanghai each appear three times across the dataset, with Beijing contributing two entries, making those three cities the dominant hubs in this slice of the market.
Among disclosed amounts, Epigenic Therapeutics leads the recent cohort with a $60M Series B out of Shanghai in September 2025, while the 2020-era entries — Harbour Biomed ($103M, Shanghai) and JW Therapeutics ($100M, Shanghai) — reflect the larger ticket sizes that characterized that period. Seven of the ten most recent rounds list amounts as undisclosed, so stage and geography are more actionable signals than raise size when prospecting in this segment right now.
Most recent rounds
13 shownRelated listings
Frequently asked
What are the largest disclosed rounds in this dataset?
Harbour Biomed tops the list at $103M (Shanghai, July 2020), followed by JW Therapeutics at $100M (Shanghai, June 2020) and CANbridge Pharmaceuticals at $43M (Beijing, December 2020). Among rounds from 2025, Epigenic Therapeutics' $60M Series B in September 2025 is the largest disclosed amount.
Which cities account for the most funded biotech companies here?
Shenzhen and Shanghai each appear three times — Shenzhen with JGene Biotechnology, BayOmics, and Salus BioMed; Shanghai with Epigenic Therapeutics, Harbour Biomed, and JW Therapeutics. Beijing follows with two entries (Taihao Biotechnology and CANbridge Pharmaceuticals). The remaining six companies are spread across Changzhou, Dongli, Changping, Tianjin, and Zhongshan, each appearing once.
What funding stages are most represented?
Seed rounds appear four times (Zhonghe Gene, BayOmics, Yuantian Bio, Jingcui Bio), Series A three times (JGene, U-Sweet, Taihao), and Series B three times (Enze Kangtai, Salus BioMed, Epigenic Therapeutics). The three 2020-era entries — CANbridge, Harbour Biomed, and JW Therapeutics — do not carry a labeled round type in this data.
How many of these rounds have disclosed funding amounts?
Six of the 13 entries report a specific dollar figure. All seven undisclosed rounds fall within October–November 2025, meaning the most recent wave of activity is difficult to size by raise amount alone. Stage and city remain the more reliable filters for that cohort.
How concentrated was Chinese biotech funding activity in late 2025?
Seven of the ten most recent entries closed between September 20 and November 27, 2025 — a roughly ten-week window. Four rounds alone closed in November 2025, suggesting a concentrated burst of deal activity heading into year-end.
Which Series B companies from 2025 are worth targeting for enterprise sales or partnership outreach?
Three Series B rounds appear from 2025: Epigenic Therapeutics ($60M, Shanghai, September 2025), Enze Kangtai ($14M, Changping, November 2025), and Salus BioMed ($7M, Shenzhen, October 2025). Epigenic's raise is the largest of the three by a wide margin and the most likely to signal active vendor procurement cycles.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.